In this episode of SARC Talk, we welcome Dr. Patrick Grohar, a recognized expert in Ewing sarcoma and the Russell G. Adderley Professor of Pediatric Oncology at the University of Michigan.
Dr. Grohar discusses the development and conduct of SARC037, a phase 1/2 clinical trial evaluating trabectedin and low-dose irinotecan to target the EWS::FLI1 transcriptional program in Ewing sarcoma. Following the publication of the SARC037 results in Nature Medicine, we explore what the findings mean and what's next—including the potential development of a follow-up study through the Children's Oncology Group.
We also discuss Dr. Grohar's career journey, research funding, collaboration, mentorship, and his vision for the future of Ewing sarcoma research.
Dr. Grohar's Laboratory Website: https://www.groharlab.org/
Read the SARC037 Nature Medicine publication here: https://www.nature.com/articles/s41591-026-04340-7
Altri episodi di "SARC Talk"



Non perdere nemmeno un episodio di “SARC Talk”. Iscriviti all'app gratuita GetPodcast.








